France's ABIONYX Pharma Q1 revenue dips
France's ABIONYX Pharma Q1 revenue dips
Overview
France biopharma firm's Q1 2026 revenue declined slightly yr/yr to €0.8 mln
No core biotech revenue as company provided bioproduct free for compassionate use
Company announced fully secured €18.7 mln capital increase and up to €14 mln bond financing
Outlook
ABIONYX Pharma says €2.6 mln in revenue is secured for 2026
Company expects financial visibility through end-2028 following €18.7 mln capital increase and bond financing
Company plans marketing authorization submission for CER-001 and full funding for Phase 2b sepsis trial
Result Drivers
NO CORE BIOTECH REVENUE - Co said it generated no core biotech revenue as bioproduct was provided free for compassionate use applications
IRIS PHARMA REVENUE - Q1 revenue came from non-strategic IRIS Pharma business, which declined slightly yr/yr
Company press release: ID:nBw47VvqYa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue |
| EUR 0.83 |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Abionyx Pharma SA is €10.50, about 260.2% above its May 28 closing price of €2.92
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)